Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 266,324	$ 375,935	[1]
Investments in equity securities	0	58,949	[1]
Receivables from licensing and collaboration agreements	478	1,751	[1]
Restricted cash	139,409	16,653	[1]
Prepaid expenses and other current assets	38,367	24,305	[1]
Total current assets	444,578	477,593	[1]
Investment in nonconsolidated entities	160,443	0
Property and equipment, net	8,701	11,816	[1]
Operating lease right-of-use assets	6,439	8,027	[1]
Intangible assets, net	24,525	26,319	[1]
Other assets	20,291	22,625	[1]
Total assets	664,977	546,380	[1]
Current liabilities:
Accounts payable	13,363	10,655	[1]
Accrued compensation and benefits	43,541	57,370	[1]
Accrued research and development liabilities	40,997	29,765	[1]
Operating lease liabilities, current portion	4,600	4,128	[1]
Deferred revenue, current portion	11,771	6,096	[1]
Accrued professional and other accrued liabilities	24,944	35,830	[1]
Total current liabilities	139,216	143,844	[1]
Term loan, net	436,221	446,445	[1]
Operating lease liabilities, net of current portion	5,833	8,981	[1]
Deferred revenue, net of current portion	18,627	3,727	[1]
Other long-term liabilities	377	5,634	[1]
Total liabilities	1,883,369	1,888,915	[1]
Commitments and contingencies (Note 8)
Redeemable convertible noncontrolling interests	645	478
Stockholders’ equity (deficit):
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized; 195,178,308 shares issued and 188,986,547 shares outstanding as of September 30, 2024, 181,274,712 shares issued and 175,082,951 shares outstanding as of December 31, 2023	195	181	[1]
Treasury stock, at cost; 6,191,761 shares as of September 30, 2024 and December 31, 2023	(275,000)	(275,000)	[1]
Additional paid-in capital	1,876,091	1,481,032	[1]
Accumulated other comprehensive income	5	31	[1]
Accumulated deficit	(2,831,213)	(2,560,501)	[1]
Total BridgeBio stockholders' deficit	(1,229,922)	(1,354,257)	[1]
Noncontrolling interests	10,885	11,244	[1]
Total stockholders' deficit	(1,219,037)	(1,343,013)	[1],[2]
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit	664,977	546,380	[1]
2029 Notes
Current liabilities:
Notes, net	738,376	736,905	[1]
2027 Notes
Current liabilities:
Notes, net	$ 544,719	$ 543,379	[1]

[1] The condensed consolidated balance sheet as of December 31, 2023 is derived from the audited consolidated financial statements as of that date.

[2] The consolidated balances as of December 31, 2023 and 2022 are derived from the audited consolidated financial statements as of those dates.